Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 May;122(5):1008-15.
doi: 10.1016/j.ophtha.2014.12.017. Epub 2015 Feb 14.

Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis

Christopher K Hwang  1 , G Baker Hubbard  1 , Amy K Hutchinson  1 , Scott R Lambert  2
Affiliations
Comparative Study

Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis

Christopher K Hwang et al. Ophthalmology. 2015 May.

Abstract

Purpose: To determine the relative effectiveness, major complications, and refractive errors associated with intravitreal bevacizumab (IVB) versus panretinal photocoagulation (PRP) to treat type 1 retinopathy of prematurity (ROP).

Design: Retrospective case series.

Participants: Consecutive infants with type 1 ROP who received either IVB or PRP and had at least 6 months of follow-up.

Methods: The data from infants treated with either IVB or PRP for type 1 ROP between 2008 and 2012 were recorded from 2 medical centers in Atlanta, Georgia.

Main outcome measures: Recurrence rate, complication rate, and refractive error.

Results: A total of 54 eyes (28 patients) with type 1 ROP were evaluated: 22 eyes (11 patients) received IVB, and 32 eyes (17 patients) received PRP. Among the 22 eyes treated with IVB, 16 eyes had zone I ROP and 6 eyes had posterior zone II ROP. The number of zone I and II ROP eyes treated with PRP were 5 and 27, respectively. Mean gestational age, birth weight, postmenstrual age at initial treatment, and follow-up period for the infants receiving IVB were 24.2 weeks, 668.1 g, 35.1 weeks, and 21.7 weeks, respectively, and for the infants receiving PRP, these were 24.8 weeks, 701.4 g, 36.1 weeks, and 34.5 weeks, respectively. Retinopathy of prematurity recurred in 3 (14%) of 22 IVB-treated eyes and in 1 (3%) of 32 PRP-treated eyes. Neither retinal detachment nor macular ectopia developed in any of the IVB-treated eyes. In PRP-treated eyes, retinal detachment developed in only 1 eye and macular ectopia developed in 5 eyes. Mean spherical equivalent and postgestational age at the last refraction for IVB-treated eyes were -2.4 diopters (D) and 22.4 months, respectively, and for PRP-treated eyes, these were -5.3 D and 37.1 months, respectively. Mean spherical equivalent for zone I ROP eyes treated with IVB and PRP were -3.7 D and -10.1 D, respectively, and for zone II ROP eyes, these were 0.6 D and -4.7 D, respectively.

Conclusions: Both IVB and PRP are effective treatment options for type 1 ROP with low complication rates. IVB was associated with less myopia than PRP, although longer follow-up was available for PRP.

PubMed Disclaimer

Conflict of interest statement

No conflicting relationship exists for any author.

Figures

Figure 1
Figure 1
Pre- and post-treatment images of the retina after intravitreal bevacizumab. Prior to treatment, plus disease with prominent tortuosity and congestion of the retinal vessels are observed in the left eye of a patient with Type 1 ROP (A). Two weeks post-treatment, the retinal vesels appear significantly less tortuous and congested (B).
Figure 2
Figure 2
Pre- and post-treatment images of the retina after pan-retinal photocoagulation. Plus disease with prominent tortuosity and congestion of the retinal vessels are observed in the left eye of a patient with Type 1 ROP prior to treatment (A). The retinal vesels appear significantly less tortuous and congested two weeks post-PRP (B).
See this image and copyright information in PMC

References

    1. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024–1028. - PubMed
    1. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–844. - PubMed
    1. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905–909. - PMC - PubMed
    1. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515–2526. - PMC - PubMed
    1. White JE, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome. J Pediatr Ophthalmol Strabismus. 1997;34(2):83–87. quiz 121-2. - PubMed

Publication types

MeSH terms

Substances